Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma

BACKGROUND: The potential therapeutic efficacy of daratumumab in natural killer T-cell lymphoma (NKTL) was highlighted when its off-label usage produced sustained remission in a patient with highly refractory disease. This is corroborated recently by a phase II clinical trial which established that...

Descripción completa

Detalles Bibliográficos
Autores principales: Mustafa, Nurulhuda, Nee, Adina Huey Fang, Chooi, Jing Yuan, Toh, Sabrina Hui Min, Chung, Tae-Hoon, Selvarajan, Viknesvaran, Fan, Shuangyi, Ng, Siok Bian, Poon, Michelle, Chan, Esther, Lee, Joanne, Chee, Yen Lin, Jeyasekharan, Anand D, Zhou, Longen, Yang, Jennifer, Chng, Wee Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256838/
https://www.ncbi.nlm.nih.gov/pubmed/34215687
http://dx.doi.org/10.1136/jitc-2020-002123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256838/
https://www.ncbi.nlm.nih.gov/pubmed/34215687
http://dx.doi.org/10.1136/jitc-2020-002123

Ejemplares similares